KRT18P58

Across TCGA pan-cancer cohorts, KRT18P58 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated KRT18P58 data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher KRT18P58 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated KRT18P58 expression acts as an unfavorable survival marker, although some lineages such as BRCA and COAD show a favorable association.

CHOL, LUSC, and TGCT are the cancer types where KRT18P58 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Quartile	All	0.142	0.788	.001	42	view →
LUSC	OS	Tertile	II,III,IV	0.497	0.781	.004	38	view →
TGCT	DFS	Tertile	All	0.476	0.772	.001	36	view →
LGG	DFS	Tertile	All	0.381	0.762	<.001	27	view →
KIRP	OS	Quartile	III,IV	0.502	0.824	.004	22	view →
SKCM	DFS	Tertile	IV	0.016	0.454	<.001	21	view →
ESCA	OS	Median	All	0.466	1.000	.016	21	view →
DLBC	OS	Tertile	All	0.053	0.936	<.001	18	view →
GBM	DFS	Tertile	All	0.088	0.249	.003	15	view →
LUAD	OS	Quartile	All	0.250	0.448	.008	14	view →
PAAD	OS	Median	All	0.472	0.662	.007	12	view →
BRCA	OS	Median	III,IV	0.947	0.878	.012	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

KRT18P58–CHOL (OS)

Open the CHOL breakdown →